Quote this publication Share Print

CARDENSIEL

-
Opinions on drugs - Posted on Jun 04 2012

Reason for request

Modification of the wording of the indication: “Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to angiotensin-converting enzyme (ACE) inhibitors, and diuretics, and optionally cardiac glycosides”.

-


Actual benefit

Important

The actual benefit of these medicinal products is substantial.


Improvement in actual benefit

V (absence)

CARDENSIEL does not provide any improvement in actual benefit (IAB V) in the management of chronic stable heart failure with reduced systolic left ventricular function in addition to angiotensin-converting enzyme (ACE) inhibitors, and diuretics, and optionally cardiac glycosides.


Contact Us

Évaluation des médicaments

See also